Stock Groups

Kiniksa Pharmaceuticals Down After Phase 3 Trial Fails to Meet Endpoint -Breaking

by Mike Robinson

[ad_1]

© Reuters

Sam Boughedda

Investing.com — The shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:) fell 7% Tuesday, after falling more than 16% premarket. This was due to the news that the Covid-19-related acute Respiratory Syndrome (ARDS), phase 3 trial for mavrilimumab (NASDAQ:) failed to meet its primary efficacy endpoint.

According to the biopharmaceutical firm, it was not possible for the primary endpoint of maintaining a proportion of patients who are alive at all times and without mechanical ventilation on day 29. Phase 3 included 582 patients.

Chairman and CEO of Kiniksa Sanj Patel said that the company believes in the “potential wide utility of mavrilimumab” and is currently evaluating the next steps. 

Patel stated that the current strategy focuses on ARCALYST, which includes the execution of recurrent pericarditis commercially, and the development vixarelimab as well as our anti-CD40 program KPL-404.

In early November, Kiniksa was added to the Analyst Focus list at JPMorgan based on the potential upside in recurrent pericarditis along with the company’s pipeline of treatments.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]